Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Bristol Myers Squibb's experimental CAR-T therapy, arlo-cel, cleared a key hurdle in a mid-stage trial for relapsed or refractory multiple myeloma. The therapy showed a statistically significant improvement in overall response rate — and even achieved complete cancer clearance in some patients. Full data will be shared at an upcoming medical conference.
Bristol Myers Squibb's experimental cell therapy, arlocabtagene autoleucel (arlo-cel), has hit its primary endpoint in a mid-stage clinical trial for patients with advanced multiple myeloma — one of the hardest-to-treat blood cancers. The trial enrolled patients who had already failed four major classes of standard treatments, making this a particularly high-stakes population.
The therapy met its main goal by demonstrating a meaningful improvement in overall response rate, and also cleared a key secondary endpoint by achieving complete responses — meaning no detectable signs of cancer — in a subset of patients. While specific numbers weren't released, Bristol Myers described the results as statistically significant and clinically meaningful, with full data to be presented at an upcoming medical meeting.
Key Takeaways:
Why it matters: Multiple myeloma affects an estimated 36,000 Americans annually and claims nearly 11,000 lives each year. For patients who've run out of standard options, a single-infusion CAR-T therapy with strong response rates could be a meaningful new lifeline.
